Status:
COMPLETED
A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
Lead Sponsor:
Alcon Research
Conditions:
AMD
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Ages 50 years and over
- Other protocol-defined inclusion and exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
April 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2003
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT00346957
Start Date
April 1 1999
End Date
April 1 2003
Last Update
March 6 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.